Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Steris said it plans to close down a plant in its Mentor, Ohio, base and lay off about 150 workers worldwide.
The layoffs represent a 2.5% cut to the workforce at Steris, which employed about 6,000 workers as of March 31, 2013, according to a regulatory filing. Read more
U.S. attorney general Eric Holder Jr. should open a criminal probe into the destruction of documents in lawsuits filed against Johnson & Johnson subsidiary Ethicon over its pelvic mesh products, a consumer advocacy group said this week.
Corporate Action Network, which according to its website was “founded to address the imbalance of power between corporations and people,” issued an open letter to Holder calling for the investigation into the documents’ destruction. A federal magistrate judge found earlier this year that Ethicon lost or destroyed documents in the multi-district litigation over its pelvic mesh devices, which are designed to treat pelvic organ prolapse and stress urinary incontinence in women. Read more
Baxter said it plans to separate its medical products and pharmaceuticals businesses into independent companies, following in the footsteps of rivals Abbott and Covidien.
“Baxter has an established history of executing successful spinoffs, and we have continued to evaluate the separation of these two businesses in response to diverging business dynamics and the rapidly changing macro-environment,” said Robert Parkinson Jr., chairman & CEO of the Deerfield Park, Ill.-based healthcare titan, in prepared remarks. “This decision underscores Baxter’s commitment to ensuring its long-term strategic priorities remain aligned with shareholders’ best interests, while improving our competitive position and performance, enhancing operational, commercial and scientific effectiveness and creating value for patients, healthcare providers, and other key stakeholders.” Read more